Clinical trials: Dose Escalation and Safety
Metabolism and Nutrition Disorder, Obesity
A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity
This study looks at a new study medicine for weight control in people with overweight or obesity. The aim of this study is to see if the study medicine is safe for people to take.
- Trial name
- NCT03479892
- Testing
- NNC0194-0499
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Novo Nordisk A/S
Healthy Subjects
GSK706769 A First Time in Human Study For Males and Females
To determine safety, tolerability and pharmacokinetics of GSK706769
- Trial name
- NCT00539201
- Testing
- GSK706769
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety and Tolerability Study of Multiple Doses of PF-06305591
Safety, tolerability and PK of repeated doses of PF-06305591 will be evaluated in young healthy volunteers toghether with food effect on relative bioavailability of solid formulation after single dose.
- Trial name
- NCT01776619
- Testing
- PF-06305591
- Where
- Belgium
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lymphoma, Non-Hodgkin
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement
This is a phase I, dose escalation, open-label, multicenter study of iodine-131 Anti-B1 Antibody for patients with non-Hodgkin's lymphoma (NHL) who have more than 25% bone marrow involvement with NHL.
- Trial name
- NCT00992758
- Testing
- Iodine-131 Anti-B1 Antibody
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Lung Cancers
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV)…
- Trial name
- NCT06713564
- Testing
- LS301-IT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Integro Theranostics
Neurogenic Detrusor Overactivity
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence).
- Trial name
- NCT05621616
- Testing
- mirabegron
- Where
- 3 sites in Philippines, Poland
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers
Investigation of safety and tolerability of BI 655088 following intravenous infusion of single rising doses and exploration of the pharmacokinetics and pharmacodynamics of BI 655088 after single dosing
- Trial name
- NCT02696616
- Testing
- BI 655088
- Where
- Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects
Study design: Randomized, double-blind, placebo-controlled, sequential dose escalation Six ascending dose cohorts are planned Primary Objective: To evaluate the safety profile of single escalating intravenous dose levels of…
- Trial name
- NCT01013064
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03511898
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Solid Tumor, Adult
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
BY101921 is a novel small molecule, being developed as a PARP7 inhibitor which acts on the PARP7 catalytic subunit, for the treatment of solid tumors.
- Trial name
- NCT06433726
- Testing
- BY101921 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT06191887
- Testing
- Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Dilated Cardiomyopathy (DCM)
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
- Trial name
- NCT07137338
- Testing
- RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Inflammation, Rheumatoid Arthritis
Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety and tolerability of single doses of Anti-IL-20 in healthy volunteers (HV) and patients with rheumatoid arthritis (RA).
- Conditions
- Inflammation, Rheumatoid Arthritis, Healthy
- Trial name
- NCT00818064
- Testing
- anti-IL-20
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Fragile X Syndrome
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
The objectives of this study are to determine the safety and tolerability of single oral doses of STX107 and to determine basic pharmacokinetic (PK) parameters following single oral doses of STX107 when administered via an oral…
- Trial name
- NCT00965432
- Testing
- STX107
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Seaside Therapeutics, Inc.
Obstructive Sleep Apnea
A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose
BAY2586116 is a new drug in development for the treatment of obstructive sleep apnea. This is a condition that causes breathing to repeatedly stop and start during sleep due to blocked upper airways.
- Trial name
- NCT04872387
- Testing
- BAY2586116
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer
Asthma
A Trial of SHR-1905 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of subcutaneous administered…
- Trial name
- NCT04800263
- Testing
- SHR-1905
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A…
- Conditions
- Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT05326516
- Testing
- Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Metastatic Cancer
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
The purpose of this study is to evaluate the safety and pharmacokinetics of ASA404 in patients with refractory or relapsed metastatic cancer with impaired renal function and with normal renal function.
- Trial name
- NCT01278758
- Testing
- ASA404, DMXAA or DXAA
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety in patients with cancer.
- Trial name
- NCT01611623
- Testing
- SNX-5422
- Volunteers
- 9 people
- Sponsor
- Esanex Inc.
Multiple Sclerosis
NOGO-A in Multiple Sclerosis FTIH
The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth. The trial is expected to involve approximately 36 patients.
- Trial name
- NCT01424423
- Testing
- GSK1223249
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.